InspireMD Presents 30-Day Follow-Up Results From The C-GUARDIANS U.S. Investigational Device Exemption Clinical Trial At VIVA23
Portfolio Pulse from Benzinga Newsdesk
InspireMD, Inc. (NASDAQ:NSPR) presented 30-day results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial at the Vascular InterVentional Advances (VIVA) meeting. The trial evaluated the safety and efficacy of the CGuard™ Carotid Stent System. The follow-up data supports the safety of the C-Guard EPS stent, with a low rate of major adverse events observed through 30 days. InspireMD anticipates reporting primary endpoint results from C-GUARDIANS in the second half of 2024 that may support a Premarket Approval (PMA) application.
November 01, 2023 | 6:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
InspireMD's positive 30-day results from the C-GUARDIANS clinical trial supports the safety of the C-Guard EPS stent, potentially boosting investor confidence in the company's product pipeline.
The positive 30-day results from the C-GUARDIANS clinical trial supports the safety of the C-Guard EPS stent, which is a key product in InspireMD's pipeline. This could potentially boost investor confidence in the company's product pipeline and its ability to secure regulatory approvals, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100